RxDoctor Payments Data

Michael Stifelman, MD

Urology · Hackensack, NJNPI 1750375564

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $952,898 of the $1,395,397 with a category attached, or 68.3%. Vascular Technology, Inc. accounts for 61.5% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $803,561 and has fallen 78.8% since, to $170,217 in 2025. Among urology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,395,397in general payments, 2019–2025

Across 526 payments — averaging $2652.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vascular Technology, Inc.$858K
  • Intuitive Surgical$496K
  • Johnson & Johnson$21K
  • Procept Biorobotics Corporation$10K
  • Conmed Corporation$8K
  • Boston Scientific$801
  • plus $2K from 19 others
$255,878in research payments, 2019–2025

Across 16 payments — averaging $15,992 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Conmed Corporation$190K
  • Biotissue Holdings Inc.$66K
$19,620in ownership & investment interests, 2019–2025

Across 7 payments — averaging $2802.86 each. An ownership or investment interest held by the physician or an immediate family member.

  • Applied Medical Corporation$20K

What the payments were for

  • Consulting fees$220,92616%
  • Speaking & faculty fees$952,89868%
  • Travel & lodging$54,2484%
  • Food & beverage$17,5261%
  • Education$149,74611%
  • Gifts$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,395,397 in reported general payments places this provider in the 95th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$167,103
Medicare patients
319
Services billed
828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron18$12,502
Tamsulosin Hcl37$583
Finasteride25$361
Alfuzosin Hcl ErAlfuzosin Hcl11$218

Paid to pharmacies, not to this prescriber.

Other urology in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →